Human embryonic stem cell-derived cardiomyocytes express SARS-CoV-2 host entry proteins: screen to identify inhibitors of infection
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection.
Article activity feed
-
SciScore for 10.1101/2021.01.22.427737: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Slide Scanner Axio Scan.Z1 (Zeiss) Methods: Surgical samples of human tissue were obtained with informed consent from Royal Papworth Hospital Research Tissue Bank and ethical approval (05/Q104/142). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The primary antibody used was sheep anti-SARS-CoV-2 nucleocapsid antibody (DA114, MRC-PPU), which was visualised with AF488 conjugated donkey anti-sheep antibody (Jackson ImmunoResearch #713-545-147) Pseudotyped virus production: Pseudotyped virus infection of … SciScore for 10.1101/2021.01.22.427737: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Slide Scanner Axio Scan.Z1 (Zeiss) Methods: Surgical samples of human tissue were obtained with informed consent from Royal Papworth Hospital Research Tissue Bank and ethical approval (05/Q104/142). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The primary antibody used was sheep anti-SARS-CoV-2 nucleocapsid antibody (DA114, MRC-PPU), which was visualised with AF488 conjugated donkey anti-sheep antibody (Jackson ImmunoResearch #713-545-147) Pseudotyped virus production: Pseudotyped virus infection of hESC-derived cardiomyocytes: For infection of hESC-derived cardiomyocytes, cells in CellCarrier-96 Ultra Plates (PerkinElmer) were incubated for 4 h with pseudotyped viral stock at the desired MOI in media. anti-SARS-CoV-2 nucleocapsid antibody (DA114, MRC-PPU)suggested: NoneIn drug screens, cells were pre-treated for 1 h before infection with either camostat, benztropine, or E64d at a final concentration of 30 μM in media; DX600 at a final concentration of 10 μM in media; ACE2 antibody (AF933; R&D Systems) at 20 μg/mL; a mix of camostat + E64d at a final concentration of 30 μM each; or DMSO at 0.6% (equivalent of the highest concentration included in drug dilutions). ACE2suggested: (GenWay Biotech Inc. Cat# 18-661-15169-0.1 mg, RRID:AB_514759)For viral infection experiments, excitation/emission laser and filter sets for two fluorescent channels were used: 405/435-480 nm (blue) for the Hoechst 33342 nuclear stain, and 488/500-550 nm (green) for GFP or the donkey anti-sheep antibody conjugated to Alexa Fluor 488 (Jackson ImmunoResearch #713-545-147). GFPsuggested: (Jackson ImmunoResearch Labs Cat# 713-545-147, RRID:AB_2340745)anti-sheepsuggested: (Jackson ImmunoResearch Labs Cat# 713-545-147, RRID:AB_2340745)Sections were then incubated overnight at 4°C with either: primary goat polyclonal antibody to Human ACE-2 (AF933; R&D; 1:100); primary rabbit monoclonal antibody to TMPRSS2 (ab92323; Abcam; 1:500); primary rabbit monoclonal antibody to B0AT1 (ab180516; Abcam; 1:300); primary rabbit monoclonal antibody to cathepsin B (ab125067; Abcam; 1:100); primary rabbit polyclonal antibody to cathepsin L (ab203028; Abcam; 1:100); or primary rabbit polyclonal antibody to furin (ab3467; Abcam; 1:500), all prepared in PBS with 1% donkey sera, 0.1% Tween-20, and 3.3 mg/mL bovine serum albumin. TMPRSS2suggested: (Abcam Cat# ab92323, RRID:AB_10585592)After 24 h, sections were washed 3x with PBS with 0.1% Tween-20 before incubation with the secondary polyclonal Donkey Anti-Goat IgG H&L antibody conjugated to Alexa Fluor 555 (ab150130; Abcam; 1:200) or Donkey Anti-Rabbit IgG H&L antibody conjugated to Alexa Fluor 555 (ab150066; Abcam; 1:200) prepared at 0.01 mg/mL in PBS with 1% donkey sera, 0.1% Tween-20, and 3.3 mg/mL bovine serum albumin, for 1 h at room temperature. Anti-Rabbit IgGsuggested: (Biorbyt Cat# orb14385, RRID:AB_10735740)The second (yellow channel) used an LED-Module 567 nm light source set at 80% intensity and 30 ms exposure time at a depth of focus of 1.88 μm to illuminate the Donkey Anti-Goat IgG antibody or Donkey Anti-Rabbit IgG H&L antibody, both conjugated to Alexa Fluor 555 (max excitation and emission of 555 and 580 respectively for both). Anti-Goat IgGsuggested: NoneThe third (far red channel) used an LED-Module 630 nm light source set at 50% intensity and 20 ms exposure time at a depth of focus of 2.09 μm to illuminate the cardiac troponin-T antibody conjugated to APC (max excitation and emission of 650 and 660 respectively). APCsuggested: NoneExperimental Models: Cell Lines Sentences Resources In total, the stock used was passaged three times in VeroE6 cells, once in Caco2 cells, and once in Calu3 cells. VeroE6suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Caco2suggested: CLS Cat# 300137/p1665_CaCo-2, RRID:CVCL_0025)The titre of the virus stock was determined by TCID50 (Median Tissue Culture Infectious Dose) assay on Huh7 cells transduced with an ACE2 expression vector. Huh7suggested: CLS Cat# 300156/p7178_HuH7, RRID:CVCL_0336)Software and Algorithms Sentences Resources Analysis was performed using FlowJo software (BD Biosciences). FlowJosuggested: (FlowJo, RRID:SCR_008520)Acquired images were saved and visualised using ZEN software (Zeiss). ZENsuggested: NoneGraphical presentation and statistical analyses were performed using GraphPad Prism version 6.07 for Windows (GraphPad Software, La Jolla, California, USA). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)RNA concentration was determined using a NanoDrop 1000 (ThermoFisher), and RNA samples subsequently stored at −70°C prior to RNA sequencing library preparation. ThermoFishersuggested: (ThermoFisher; SL 8; Centrifuge, RRID:SCR_020809)Data Analysis: Processing and analysis of next generation sequencing data: All next generation sequencing data were aligned using HiSAT2 (http://daehwankimlab.github.io/hisat2/) to the Homo sapiens reference genome GRCh38/hg38. HiSAT2suggested: (HISAT2, RRID:SCR_015530)Reads were trimmed prior to alignment using Trim Galore, using Phred quality score for base calling cut-off of 20, corresponding to a maximum error of 1 in 100 bases and with a maximum trimming error rate of 0.1 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/)27. Trim Galoresuggested: (Trim Galore, RRID:SCR_011847)Phredsuggested: (Phred, RRID:SCR_001017)Trimmed and aligned sequence files were imported as BAM files into SeqMonk (v1.42.0) for visualization and analysis (http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/). SeqMonksuggested: (SeqMonk, RRID:SCR_001913)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-